文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

免疫功能受损的成人血液病患者接种mRNA-1273新冠疫苗应答的定量分析

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.
PubMed 文献 · Blood Adv · 2022-01-01

该前瞻性研究定量检测723例严重免疫功能受损的血液病患者接种2剂mRNA-1273(Spikevax/Moderna)疫苗期间及之后的血清S1 IgG抗体,以S1 IgG≥300结合抗体单位(BAU)/mL为 adequate 标准,结果>50%患者达到该标准,镰状细胞病和慢性髓性白血病患者全部达标,而淋巴瘤、接受伊布替尼治疗的慢性淋巴细胞白血病及嵌合抗原受体T细胞治疗受者应答率低。

要点

  • 2剂mRNA-1273后>50%的严重免疫功能受损血液病患者获得S1 IgG≥300 BAU/mL。
  • 镰状细胞病和慢性髓性白血病患者均获得足够的抗体浓度。
  • 淋巴瘤、伊布替尼治疗的慢性淋巴细胞白血病及CAR-T受者应答率低。

核心结论

  • 尽管患者因疾病或其治疗而严重免疫功能受损,>50%的患者在2剂mRNA-1273后仍获得S1 IgG≥300 BAU/mL;接受化疗、造血干细胞移植后不久或合并慢性移植物抗宿主病的血液病患者不应被排除在疫苗接种之外。

研究设计与样本

  • 前瞻性研究,纳入723例因疾病或其治疗而严重免疫功能受损的血液病患者,定量检测接种2剂mRNA-1273(Spikevax/Moderna)期间及之后的血清S1 IgG抗体;以S1 IgG≥300 BAU/mL为 adequate 标准;该试验在荷兰试验注册中心注册号为#NL9553。

主要发现

  • 2剂mRNA-1273后>50%的患者获得S1 IgG≥300 BAU/mL。
  • 所有镰状细胞病或慢性髓性白血病患者均获得足够的抗体浓度。
  • 约70%的慢性移植物抗宿主病(cGVHD)、多发性骨髓瘤或未经治疗的慢性淋巴细胞白血病(CLL)患者获得S1 IgG≥300 BAU/mL。
  • 在髓系恶性肿瘤中,芦可替尼或去甲基化治疗而非大剂量化疗削弱了应答。
  • 淋巴瘤患者、接受伊布替尼治疗的CLL患者及嵌合抗原受体T细胞受者的应答低。

关键数值与推荐

  • 获得S1 IgG≥300 BAU/mL被视为 adequate,该值代表健康个体中获得的S1 IgG浓度下限,并与有效的病毒中和作用相关。
  • 自体外周血造血干细胞移植后达到足够抗体浓度的最短时间间隔:多发性骨髓瘤<2个月,淋巴瘤8个月,异基因HCT后4至6个月。

临床怎么用

  • 接受化疗、造血干细胞移植后不久或合并慢性移植物抗宿主病的血液病患者不应被排除在疫苗接种之外。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccination guidelines for patients treated for hematological diseases are typically conservative. Given their high risk for severe COVID-19, it is important to identify those patients that benefit from vaccination. We prospectively quantified serum immunoglobulin G (IgG) antibodies to spike subunit 1 (S1) antigens during and after 2-dose mRNA-1273 (Spikevax/Moderna) vaccination in hematology patients. Obtaining S1 IgG ≥ 300 binding antibody units (BAUs)/mL was considered adequate as it represents the lower level of S1 IgG concentration obtained in healthy individuals, and it correlates with potent virus neutralization. Selected patients (n = 723) were severely immunocompromised owing to their disease or treatment thereof. Nevertheless, >50% of patients obtained S1 IgG ≥ 300 BAUs/mL after 2-dose mRNA-1273. All patients with sickle cell disease or chronic myeloid leukemia obtained adequate antibody concentrations. Around 70% of patients with chronic graft-versus-host disease (cGVHD), multiple myeloma, or untreated chronic lymphocytic leukemia (CLL) obtained S1 IgG ≥ 300 BAUs/mL. Ruxolitinib or hypomethylating therapy but not high-dose chemotherapy blunted responses in myeloid malignancies. Responses in patients with lymphoma, patients with CLL on ibrutinib, and chimeric antigen receptor T-cell recipients were low. The minimal time interval after autologous hematopoietic cell transplantation (HCT) to reach adequate concentrations was <2 months for multiple myeloma, 8 months for lymphoma, and 4 to 6 months after allogeneic HCT. Serum IgG4, absolute B- and natural killer-cell number, and number of immunosuppressants predicted S1 IgG ≥ 300 BAUs/mL. Hematology patients on chemotherapy, shortly after HCT, or with cGVHD should not be precluded from vaccination. This trial was registered at Netherlands Trial Register as #NL9553.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Haggenburg S, Lissenberg-Witte BI, van Binnendijk RS, et al. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Adv. 2022. PMID: 35114690. doi:10.1182/bloodadvances.2021006917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。